Suppr超能文献

氨曲南从母体向胎儿转运的药代动力学研究

[Pharmacokinetic study of aztreonam transfer from mother to fetus].

作者信息

Obata I, Yamato T, Hayashi S, Imakawa N, Hayashi S

机构信息

Department of Obstetrics and Gynecology, Kosei Hospital.

出版信息

Jpn J Antibiot. 1990 Jan;43(1):70-80.

PMID:2348554
Abstract

Aztreonam (AZT) was administered to 73 cases and its usefulness and safety were evaluated upon review of the transfer of the drug into maternal blood, umbilical cord blood and amniotic fluid. The result obtained are summarized as follows. 1. AZT was intravenously administered by single injection to obtain actual data. Based on the data, theoretical changes of drug concentrations in serum in mother were reviewed according to the lapse of time. Drug concentration in maternal blood showed its peak immediately after administration and gradually decreased thereafter. Umbilical cord blood concentration showed a lower peak, which was reached with a slight delay to the Tmax for maternal blood concentration, then decreased. The decrease, however, was more moderate than the decrease in maternal blood concentration and, according to the theoretical values, umbilical cord blood concentration was higher than maternal blood concentration at 2.23 or 2.24 hours after administration. AZT concentrations in amniotic fluid slowly increased after administration and were higher than umbilical cord blood concentrations at 1.68, 1.73 hours after administration, higher than maternal blood concentrations at 1.82, 1.85 hours after administration, and they reached their peak somewhat later. Subsequently, high concentrations of AZT in amniotic fluid were maintained for a long time. The result suggests that AZT is useful for prophylaxis and treatment of amniotic fluid infections. 2. Theoretical values were analyzed by applying two-compartment model and three-compartment model to the actually-measured values, and each parameter was compared. T 1/2 of AZT concentrations in maternal blood and in umbilical cord were 1.29 hours, 1.29 hours, 2.14 hours, 2.00 hours; Cmax 187.09 micrograms/ml, 184.15 micrograms/ml, 30.63 micrograms/ml, 30.66 micrograms/ml and AUC 153.25 micrograms.hr/ml, 153.40 micrograms.hr/ml, 123.19 micrograms.hr/ml, 123.09 micrograms.hr/ml respectively showing approximate values. Cmax values of AZT in amniotic fluid were 47.08 micrograms/ml, 47.74 micrograms/ml; AUC 948.03 micrograms.hr/ml, 1,028.70 micrograms.hr/ml also showing approximate values. However, volume of distribution of umbilical cord blood and amniotic fluid showed a difference according to compartment model. 3. It was considered from the above results that application of only two-compartment open model would make analysis possible when only T 1/2, Cmax and AUC values must be measured for mother-to-fetal transfer of a drug. 4. No subjective and objective side effects nor abnormal laboratory values were observed in any of these cases (both mothers and fetuses).

摘要

对73例患者使用氨曲南(AZT),通过回顾药物向母体血液、脐带血和羊水的转运情况,评估其有效性和安全性。所得结果总结如下。1. 通过单次静脉注射给予氨曲南以获取实际数据。基于这些数据,根据时间推移回顾了母体血清中药物浓度的理论变化。母体血液中的药物浓度在给药后立即达到峰值,随后逐渐下降。脐带血浓度峰值较低,达到峰值的时间比母体血液浓度的达峰时间(Tmax)稍有延迟,然后下降。然而,其下降比母体血液浓度的下降更为平缓,根据理论值,给药后2.23或2.24小时脐带血浓度高于母体血液浓度。羊水内的氨曲南浓度在给药后缓慢上升,在给药后1.68、1.73小时高于脐带血浓度,在给药后1.82、1.85小时高于母体血液浓度,且达到峰值的时间稍晚。随后,羊水内的高浓度氨曲南长时间维持。结果表明氨曲南对预防和治疗羊水感染有效。2. 将二室模型和三室模型应用于实测值进行理论值分析,并比较各参数。母体血液和脐带血中氨曲南浓度的半衰期(T 1/2)分别为1.29小时、1.29小时、2.14小时、2.00小时;峰浓度(Cmax)分别为187.09微克/毫升、184.15微克/毫升、30.63微克/毫升、30.66微克/毫升,曲线下面积(AUC)分别为153.25微克·小时/毫升、153.40微克·小时/毫升、123.19微克·小时/毫升、123.09微克·小时/毫升,各值相近。羊水中氨曲南的Cmax值分别为47.08微克/毫升、47.74微克/毫升;AUC分别为948.03微克·小时/毫升、1028.70微克·小时/毫升,也相近。然而,脐带血和羊水的分布容积根据房室模型显示出差异。3. 从上述结果认为,当仅需测定药物从母体到胎儿转运的T 1/2、Cmax和AUC值时,仅应用二室开放模型即可进行分析。4. 在所有这些病例(包括母亲和胎儿)中均未观察到主观和客观的副作用,实验室值也未出现异常。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验